Afatinib vs Erlotinib as 2nd TKI After Failure to 1st TKI and Chemotherapy for Metastatic NSCLC
Status:
Completed
Trial end date:
2014-12-01
Target enrollment:
Participant gender:
Summary
The investigators prospectively evaluated in this study the efficacy and safety profiles of
afatinib as 3rd or 4th line treatment after prior failure to systemic chemotherapy and
first-generation EGFR-TKI under a Boehringer Ingelheim sponsored Compassionate Use Program
(CUP), with comparison of our historical cohort who received erlotinib after previous failure
to systemic chemotherapy and first-generation EGFR-TKI.